Lecture 18- HBV pathogenesis Flashcards

1
Q

what cancer does HBV cause?

A

liver cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

HBV history

A

1965- australian antigen in Aboriginal, reacted with serum from a haemophilia patient
1968- antigen was particulate consisting predominantly of spherical particles and filamentous forms
1970- additional double shelled particles found
1979- full genome sequence published

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

HBV is part of what family?

A

Hepadnaviridae virus family

1st member

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

route of infection for HBV

A

blood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what type of virus is HBV?

A

pararetrovirus- DNA genome with an RNA intermediate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

HBV-like viruses that have been discovered

A

orthohepadnaviruses

avihepadnaviruses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what bird HBV can infect human cells?

A

bat HBV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

where is chronic HBV highly prevalent?

A

asia pacific and africa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

rates of HBsAg positivity in indigenous australians

A

10x higher

- novel C4 subgenotype (not present anywhere else in the world)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

how many people in australia with chronic HBV?

A

239 000 person

-90 000 unaware they are infected

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

why wont our preventative vaccination program help?

A

only helps for those that have not been infected

- negligible impact on the number of people with chronic HBV infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what is HBsAg

A

a marker of chronic infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

4 phases of the natural history of CHB

A
  1. immunotolerance- no liver damage, no activity of immune system high levels of DNA
  2. immunoactive phase- DNA levels fluctuate, maybe clearing of infection
  3. low replicative phase- nothing appears to be happening, inactive carriers (not treated at this stage), viral integration occurs (5x more likely to develop liver disease)
  4. high replicative phase- immune system wakes up again, stimulates immune response, liver damage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

when is HBeAg + and -

A

immunoactive phase- HBeAg +

high replicative phase- HBeAg -

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

natural history of chronic HBV infection

A
acute infection
chronic hepatitis
cirrhosis
liver cancer
death 
30-50 years
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

under normal circumstances, HBV is not…

A

cytopathic
- liver damage is caused by host’s cellular immune response to HBV infected hepatocytes as part of immune clearance phase (cytotoxic T cell clearance)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

HBV pathogenesis represents?

A

the outcome of the interplay between the virus, the hepatocyte, and hosts immune response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

how many major genotypes in CHB?

A

9 (A to I)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

which genotype has more severe disease progression?

A

genotype C
C> B
D>A

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

what is perinatal/vertical transmission? which genotypes?

A

mother to baby- shortly after birth will develop unless treated
genotypes B and C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

which genotypes for horizontal transmission?

A

genotypes A, D-H

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

what is unique about genotype J?

A

combination of orangutan and human virus (Japan)

- created his own virus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

what is unique about A1 genotype ?

A

Genotype A prevalent in sub-saharan africa

- but also rapid progression to liver cancer in black american boys NOT girls

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

which genotype is the most widespread?

A

genotype D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

HCC

A

hepatocellular carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

mechanisms by which we think HBV causes HCC

A
  • high levels of HBV replication
  • persistent HBsAg protein (envelope protein)
  • truncated HBV proteins (preS deletions)
  • integrated HBV DNA (viral DNA integration)
  • genotype (C is most oncogenic)
  • splicing/novel proteins?
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

pgRNA (pregenomic RNA) role

A

RNA intermediate

  • plays a critical role in viral replication
  • the mRNA for core and polymerase proteins
  • transcriptional template for DNA synthesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

cause of high mutation frequency

A

absence of proof reading during reverse transcription

- results in quasispecies pool of mutant viruses dependent on immune pressure

29
Q

shape of HBV genome

what does this allow for?

A

circular

  • makes longer RNA than genome
  • 3.5kb RNA (longest piece of RNA)
30
Q

HBsAg

A

Hep B surface antigen

- envelope protein

31
Q

HBcAg

A

Hep C core antigen

- capsid protein

32
Q

HBeAg

A

Hep B e antigen

- secreted truncated form of HBcAg

33
Q

Hep B polymerase

A
  • multi function enzyme

DNA polymerase, reverse transcriptase, RNase H

34
Q

HBxAg

A

hepB x antigen

  • generalised transactivator
  • only occurs in mammalian hepadnaviruses
  • critical for expression of cccDNA (viral expression)
35
Q

what is the Pre-S1 domain important for?

A

Pre-S1 domain of the HBV large envelope protein critical for entry

36
Q

cellular receptor that facilitates entry through binding to Pre-S1 protein

A

sodium taurocholate co-transporting polypeptide (NTCP)

37
Q

other role of NTCP

A

uptake of conjugated bile salts, metabolites, and drugs from portal blood into hepatocytes

38
Q

the HBV replication cycle

A
  1. virus binds to NTCP receptor and enters hepatocyte
  2. de-envelopment- envelope of virus removed, nuclear capsid remains, encodes dsDNA
  3. dsDNA enters nucleus
  4. circular genome has gap in positive strand, forms a complete dsDNA
  5. converted into cccDNA then converted to minichromosome
  6. cccDNA- transcriptional template for all the viral RNAs or
  7. pgRNA- encapsulated in nuclear capsid with polymerase protein
  8. pgRNA reverse transcribed into minus sense DNA
  9. RNAsH chops up DNA, plus sense DNA forms
  10. replication cycle occurs within nuclear capsid
  11. coated in envelope protein, leave cell and infect more cells OR
    before coating, goes back to nucleus, make more of this cccDNA due to nucleus localisation signal (replenishment pathway)
39
Q

why is cccDNA bad?

A

covalently closed circular DNA

- very important, major barrier to cure

40
Q

cccDNA in those who have cleared acute infection

A

people who have cleared their acute infection still have cccDNA in nucleus
- go into immunosuppressive drug therapy in future, hepB emerges

41
Q

what do current therapies for hepB target and not target?

A

target- viral replication outside in the cytoplasm

not target- cccDNA hiding away in nucleus

42
Q

why are drugs for HepC more successful (curable) compared to HepB?

A

HepC- whole lifecycle out in cytoplasm, no reservoir

HepB- has cccDNA in nucleus

43
Q

major integration pathway in HBV replication cycle

A

HepB can make linear DNA, integrate into our DNA, 10% of the time, integration associated with liver cancer

44
Q

virion production

A

10*12-13 virions per day

45
Q

mutational frequency

A

high mutational rate; lack of proofreading capacity of HBV Reverse transcriptase

46
Q

biological implications of quasispecies

A
  • escape mutants to immune response
  • escape mutants to vaccination
  • resistance to antiviral therapy
47
Q

current treatment for HBV

A
  • nucleoside/nucleotide RT inhibitors (NAs)

- immune modulators - IFN-alpha

48
Q

what is bad about current treatment?

A

these are not cures (due to persistence of cccDNA)

  • does not target the viral nuclear reservoir of cccDNA
  • HBV readily develops resistance to most NAs in setting of monotherapy
  • also doesnt impact integrated HBV DNA
49
Q

recent drug that has shown no resistance

A

tenofovir

50
Q

where do the phases of HBV lifecycle occur?

A

nuclear (cccDNA) and cytoplasmic phases

51
Q

what does cccDNA produce?

A

continual source of viral mRNAs and proteins which are associated with disease progression
- HBsAg, HBx antigen

52
Q

two major barriers to curing CHB

A
viral
- cccDNA
- HBsAg -continual source
immunological
- T cell exhaustion
- emerging role of inadequate B cell responses
53
Q

explain the immunological barrier to CHB cure

A

T cell exhaustion
- T cells dont work very well to clear infected cells, wake up now and then, causing immune system to flare, produce T cell activity, in some people this clears infections, most people not enough to clear infection

inadequate B cell responses

54
Q

functional cure

A

cleared the viral load- undetectable serum DNA
no activity of virus
but still has cccDNA- not transcriptionally active, therefore allow treatment cessation

55
Q

complete cure

A

cccDNA clearance

56
Q

what suggests that functional cure is a realistic goal?

A

functional HBV cure (HBsAg seroclearance) is observed in a small number of patients, either spontaneously or in setting of antiviral therapy

57
Q

viral targets to cure HBV infection

A
  • RNA interference
  • targeting HBsAg
  • polymerase inhibitors
  • inhibition of nucleocapsid assembly (prevent recycling to nucleus to make more cccDNA)
  • targeting cccDNA (tried with CRISPR-Cas9, but making new molecule, dont know what it will do)
  • entry inhibitors (block entry of HepB)
  • likely need a combination that is going to hit various parts of the viral replication cycle
58
Q

combination therapy for HBV cure

A

combination therapy with direct antiviral and immune restoration

59
Q

immune restoration as therapy for HBV

positive and problem?

A

stimulate the immune response
- restore phenotype of exhausted T cell response
PROBLEM
- if you have liver cancer, want to activate every cell for an immune response, you will activate liver cells and kill liver as well

60
Q

continued expression of HBsAg is associated with?

A

disease progression–>liver cancer

- failure to clear HBsAg prior to age 50, associated with increased risk of HCC, even in absence of detectable viremia

61
Q

HBV splice variants are associated with?

A

liver cancer

62
Q

how are spliced transcripts replicated?

A

by WT polymerase in trans (virus) as spliced transcripts do not encode Pol

63
Q

how much viral RNA and DNA is produced by splicing?

A

50%- huge part of viral pool

64
Q

what is the most common transcript and what does it encode?

A

Sp1 encodes a novel protein- hepatitis B splice protein (HBSP)

65
Q

what does splicing remove and what is the consequence?

A

removes cis-acting sequences which promote circular DNA, leading to linear DNA

  • linear DNA integrates into host genome
  • integration strongly associated with liver cancer
66
Q

what is HBSP associated with?

A

increased cell proliferation
increased with liver disease progression
promotes carcinogenic effects in the liver

67
Q

results from a pilot study to assess association between splice variants and cancer?

A

patients with liver cancer had higher median secrete Sp/wt HBV levels than those with chronic HBV infection alone

68
Q

results from taiwanese cohort study to assess association between splice variants and cancer?

A

subjects with spHBV DNA level were 8.5 times more likely to develop liver cancer
- if splice variants formed more than 20% of viral pool, then 23.3 times more likely to get HCC

69
Q

potential biomarker of liver cancer?

A

spliced DNA